Clinical trial
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in…
NCT00398489 · Technical University of Munich, Other · Unknown status
Key facts
| NCT number | NCT00398489 |
|---|---|
| Title | Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery |
| Official title | Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON] |
| Lead sponsor | Technical University of Munich, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | trastuzumab, anastrozole, cyclophosphamide, docetaxel, epirubicin hydrochloride, goserelin acetate, tamoxifen citrate, adjuvant therapy, conventional surgery, neoadjuvant therapy and 1 more |
| Enrollment | 94 |
| Start date | Oct 1, 2006 |
| First posted | Nov 10, 2006 |
| Last update posted | Nov 9, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: